Table 3 Treatment outcomes
Outcome variable | 5-years OS ± SE | p | 5-years EFS ± SE | p | 5-years CIR ± SE | p |
|---|---|---|---|---|---|---|
Overall | 89.5 ± 4.0% | 87.6 ± 4.3% | 7.1 ± 3.5% | |||
B-cell ALL | 90.5 ± 2.4% | 88.7 ± 2.6% | 6.4 ± 2.0% | |||
T-cell ALL | 86.0 ± 6.2% | 83.2 ± 7.2% | 7.4 ± 4.0% | |||
NCI risk | ≤ 0.05 | ≤ 0.05 | ||||
Standard risk | 94.2 ± 2.0% | 91.9 ± 2.4% | 5.4 ± 1.9% | |||
High risk | 81.6 ± 6.1% | 81.2 ± 6.0% | 8.9 ± 3.8% | |||
WBC count | ≤ 0.05 | ≤ 0.05 | ≤ 0.05 | |||
< 50 × 109/L | 94.5 ± 1.9% | 92.3 ± 2.3% | 5.2 ± 1.8% | |||
≥ 50 × 109/L | 79.0 ± 7.1% | 78.5 ± 7.0% | 10.3 ± 4.5% | |||
Extra-medullary status, B-cell | ≤ 0.05 | |||||
No | 90.8 ± 2.4% | 88.8 ± 2.7% | 6.5 ± 2.1% | |||
Yes | 88.4 ± 10.8% | 86.0 ± 8.9% | 4.9 ± 5.2% | |||
Extra-medullary status, T-cell | ||||||
No | 89.3 ± 6.6% | 86.0 ± 7.6% | 3.6 ± 3.7% | |||
Yes | 73.3 ± 18.1% | 72.7 ± 18.5% | 27.3 ± 18.5% | |||
Cytogenetic subtype | ≤ 0.05 | |||||
Normal | 92.8 ± 4.4% | 90.5 ± 4.7% | 4.6 ± 2.9% | |||
ETV6/RUNX1 | 95.9 ± 4.2% | 92.7 ± 5.4% | 3.5 ± 3.6% | |||
Hyperdiploidy | 93.1 ± 3.3% | 90.1 ± 3.7% | 5.6 ± 2.6% | |||
MLLR | 60.7 ± 34.6% | 55.4 ± 29.6% | 25.8 ± 22.1% | |||
t(1;19)/TCF3-PBX1 | 65.0 ± 31.5% | 58.7 ± 25.8% | 31.2 ± 23.7% | |||
Others | 90.3 ± 4.3% | 88.5 ± 4.4% | 6.5 ± 3.1% | |||
Cytogenetic group | ≤ 0.05 | ≤ 0.05 | ≤ 0.05 | |||
MLLR + t(1;19) | 63.1 ± 23.6% | 57.2 ± 20.2% | 29.5 ± 17.1% | |||
All others | 92.5 ± 2.1% | 90.0 ± 2.5% | 4.4 ± 1.8% | |||
Day 15 bone marrow | ≤ 0.05 | ≤ 0.05 | ≤ 0.05 | |||
M1 | 92.5 ± 2.1% | 91.1 ± 2.3% | 5.1 ± 1.7% | |||
M2 | 63.0 ± 26.9% | 55.9 ± 29.6% | 34.6 ± 25.5% | |||
M3 | 46.9 ± 53.9% | 40.1 ± 54.1% | 23.8 ± 27.8% | |||
Day 15 MRD | ≤ 0.05 | ≤ 0.05 | ≤ 0.05 | |||
< 0.01% | 93.6 ± 2.8% | 91.9 ± 3.1% | 5.6 ± 2.5% | |||
≥ 0.01% | 79.1 ± 7.4% | 74.7 ± 8.3% | 15.0 ± 6.2% | |||
MRD transition (D15 → D29) | ≤ 0.05 | ≤ 0.05 | ||||
N → N | 94.6 ± 2.6% | 92.9 ± 2.9% | 5.7 ± 2.5% | |||
Y → N | 83.1 ± 7.2% | 77.4 ± 8.4% | 16.0 ± 7.0% | |||
Y → Y | 71.2 ± 20.1% | 71.1 ± 20.1% | 10.0 ± 11.0% | |||
Rapidity of response | ≤ 0.05 | ≤ 0.05 | ≤ 0.05 | |||
RER | 92.8 ± 2.1% | 91.5 ± 2.3% | 5.2 ± 1.8% | |||
SER | 72.3 ± 14.7% | 66.0 ± 16.2% | 20.0 ± 11.8% | |||
Post-induction regimen | ≤ 0.05 | |||||
Arm A | 94.0 ± 2.3% | 91.8 ± 2.6% | 5.7 ± 2.1% | |||
Arm B | 91.1 ± 4.8% | 89.5 ± 4.8% | 2.9 ± 2.2% | |||
Arm C | 80.1 ± 7.6% | 79.3 ± 7.5% | 12.0 ± 5.4% | |||
Arm assignment history | ≤ 0.05 | ≤ 0.05 | ≤ 0.05 | |||
A → A | 94.2 ± 2.2% | 92.5 ± 2.5% | 5.1 ± 2.0% | |||
A → C | 90.3 ± 10.2% | 83.1 ± 13.2% | 8.0 ± 8.5% | |||
B → B | 93.5 ± 4.0% | 91.9 ± 4.0% | 2.6 ± 2.0% | |||
B → C | 56.7 ± 0.26% | 52.2 ± 27.1% | 41.4 ± 25.1% | |||
C → C | 93.6 ± 6.3% | 91.6 ± 4.8% | 2.5 ± 2.6% | |||
Gender | ||||||
Female | 86.7 ± 4.1% | 85.4 ± 4.2% | 6.6 ± 2.6% | |||
Male | 92.5 ± 2.8% | 90.4 ± 3.1% | 7.7 ± 2.8% | |||
Gender vs. treatment arm, female | ≤ 0.05 | ≤ 0.05 | ≤ 0.05 | |||
Arm A | 93.6 ± 3.4% | 91.1 ± 3.7% | 5.9 ± 3.0% | |||
Arm B | 86.0 ± 8.2% | 85.3 ± 7.2% | 2.6 ± 2.7% | |||
Arm C | 71.3 ± 15.3% | 69.7 ± 15.1% | 17.2 ± 11.3% | |||
Gender vs. treatment arm, male | ||||||
Arm A | 94.4 ± 3.0% | 92.4 ± 3.2% | 6.8 ± 3.1% | |||
Arm B | 100.0 ± 0.0% | 95.4 ± 4.8% | 4.4 ± 4.6% | |||
Arm C | 85.7 ± 7.9% | 85.1 ± 7.5% | 11.5 ± 6.6% | |||
Down syndrome | ||||||
No | 90.8 ± 2.4% | 88.8 ± 2.7% | 6.8 ± 2.1% | |||
Yes | 89.0 ± 10.8% | 85.9 ± 8.3% | 0.0% | |||